Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Eastpond Laboratories Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, which suggests that each active application is being reviewed in a separate administrative section. This distribution across 2 distinct art units indicates that the company's current applications cover different technical aspects of biotechnology. With 2 pending office actions, the company must manage 2 separate sets of deadlines and examiner requirements.
NGUYEN, NGHI V is the busiest examiner with 1 busiest examiner pending office action. Since there are 2 pending office actions in total, the workload is distributed, with NGUYEN, NGHI V managing 1 of the 2 active cases. This means that the company's prosecution efforts are split between 2 distinct examiners, each handling a single matter. The presence of 1 busiest examiner pending office action alongside 2 total actions indicates a balanced workload across the assigned examiners. Practitioners should be prepared to address the specific concerns of both NGUYEN, NGHI V and the other examiner involved in the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| CONSTANTINE, CHARLES Z | 1 | 58.9% | +49.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17884516 | METHOD OF PROMOTING CELLULAR HYDRATION BY ENHANCING INTRACELLULAR PERMEATION | NGUYEN, NGHI V | 81d overdue |
| 17576722 | COMPOSITIONS AND METHODS OF PROMOTING CELLULAR HYDRATION | CONSTANTINE, CHARLES Z | 74d overdue |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17884516 | METHOD OF PROMOTING CELLULAR HYDRATION BY ENHANCING INTRACELLULAR PERMEATION | NGUYEN, NGHI V | 1653 | §103 | Final Rejection | 81d overdue | Pending | Aug 09, 2022 |
| 17576722 | COMPOSITIONS AND METHODS OF PROMOTING CELLULAR HYDRATION | CONSTANTINE, CHARLES Z | 1657 | §112 | Non-Final OA | 74d overdue | Pending | Jan 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial